ClinicalTrials.gg
RecruitingNCT06273644Updated Mar 27, 2026

Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment

An interventional study of Carbohydrates in Porphyria, Acute Intermittent, sponsored by Nordlandssykehuset HF. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Nordlandssykehuset HF · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main aim of this clinical trial is to learn about the effect of carbohydrate-rich diet as a treatment for AIP (acute intermittent porphyria).

Aim: Investigate the diet's impact on tissue and serum glucose, plasma insulin, cytokine levels, amino acids, and gut microbiota in AIP, and their correlation with PBG (Porphobilinogen).

Aim: Assess the diet's effect on AIP symptoms and health status in AIP. Aim: Measure the effect of a high-carbohydrate diet on mitochondrial activity in AIP Aim: Map and detect potential mutations in mitochondrial genomic DNA in AIP Aim: Discover new markers in AIP through RNA sequencing and machine learning.

Participants will follow two diet plans, a 4-week intervention with 60-65 E% carbohydrates and a 4 week intervention with 40-45 E% carbohydrates.

Read the detailed description

Acute intermittent porphyria (AIP) is an inherited disease that leads to the accumulation of porphobilinogen (PBG), resulting in severe abdominal pain, paralysis, fatigue, low-grade inflammation, and an increased risk of kidney failure and liver cancer. Studies at the cellular level and in mice have shown that elevated levels of glucose and insulin can affect heme synthesis, potentially reducing PBG levels. The investigators have previously demonstrated that individuals with AIP consume less carbohydrate (E% 40) than recommended. The investigators aim to conduct a crossover study involving 50 participants with AIP, where 50% will be subjected to a 4-week intervention with 60-65 E% carbohydrates, while the other half will consume 40-45 E% carbohydrates for 4 weeks. After a 4-week intervention-free period, the two groups will switch to the respective carbohydrate percentages. Symptoms, PBG levels, continuous tissue glucose, plasma/serum insulin, glucose, cytokines, amino acid levels, microbiota in the gut, body composition, and physical activity measured using accelerometers will be assessed before and after each intervention and compared. Mitochondrial activity will be assessed at the cellular level as oxidative activity. Mutations in mitochondrial DNA and RNA will also be examined since defects in oxidative energy metabolism are known to be associated with inflammation and cancer. The work will be carried out at Nordland Hospital and at the University of Oslo. The study will be coordinated and conducted by the Postdoc and partners at Nordland Hospital, Karolinska University Hospital Stockholm and Norrland University Hospital, Umeå, the University of Oslo, the Arctic University of Tromsø, and Nord University. Clinical nutritionists will create dietary plans, and bioengineers will perform analyses. Stay abroad for postdoc, and research cooperation, with porphyria researchers at UTMB, Texas and MGH, Boston, US.

02

Conditions studied

  • Porphyria, Acute Intermittent
03

In context

Porphyria, Acute Intermittent

21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.

This study's planned enrollment of 50 is above the median of 20 across 11 interventional studies indexed under Porphyria, Acute Intermittent.

Browse Porphyria, Acute Intermittent studies →

Lead sponsor

Nordlandssykehuset HF is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AIP

Exclusion criteria

Exclusion Criteria:

  • Not having diagnosis of AIP
  • Undergoing treatment as part of other clinical research on AIP
  • Pregnancy
  • Diabetes
  • Below 18 years of age
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    60-65 E% Carbohydrates

    Diet plan A with 60-65 E% Carbohydrates in 4 weeks

    Other: Carbohydrates

  • Active comparator
    40-45% Carbohydrates

    Diet plan B with 40-45 E% Carbohydrates in 4 weeks

    Other: Carbohydrates

Interventions

  • OtherCarbohydrates

    Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.

06

What researchers measure

Primary outcomes

  1. Change in Urine Porphobilinogen/creatinine

    AIP biochemical disease activity. First morning Urine Porphobilinogen/creatinine. Change from baseline before diet A to immediately after diet A, and change from baseline before diet B to immediately after diet B

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  2. Urine Porphobilinogen/creatinine concentration, percentage change of repeated measurements

    AIP biochemical disease activity, repeated measurements Percentage change in the median of repeated measurements of Urine Porphobilinogen/creatinine concentrations between Diet A and Diet B The repeated measurements in urine analyzed in urine samples from Day 1 ,4, 8, 11, 15, 18, 22, 25 and 29 of Diet A and of Diet B, and calculated median of Urine Porphobilinogen/creatinine concentration for diet A and median for diet B

    Time frame: Day 1 ,4, 8, 11, 15, 18, 22, 25 and 29 of Diet Intervention A and of Diet Intervention B

Secondary outcomes

  1. Number of Hospitalizations,sick leaves, and doctor visits due to AIP

    Using questionnaire counting Number of hospitalizations, sick leaves, and doctor visits due to AIP * In the 4 weeks before Diet A, measured at baseline immediately before Diet A * In the 4 weeks of Diet A, measured immediately after Diet A. * In the 4 weeks before Diet B, measured at baseline immediately before Diet B * in the 4 weeks of Diet B, measured immediately after Diet B

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  2. Health status

    A standardized questionnaire assessing health (RAND-36) with a 4-week time frame from 0 (worst functioning) to 100 (best functioning), where 2 to 5 points represent a clinically meaningful difference based on data from other chronic diseases.

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  3. Plasma Glucose level

    Plasma glucose concentration

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  4. Interstitial fluid glucose level

    Glucose measured in the interstitial fluid (ISF) Measuring is performed continuously by ISF glucose sensor FreeStyle Libre 3 in the 4 weeks of Diet A and in the 4 weeks of Diet B. Outcome is percentage change in the mean of repeated measurements between Diet A and Diet B. Each tissue glucose sensor lasts 14 days, and hence the outcome measure will be assessed each 14 days, and read in the LibreView program. The sensor is placed on the back of the participants upper arm

    Time frame: Day 15 and 29 of diet A and day 15 and 29 of diet B

  5. Number of hypoglycemic events

    Tissue glucose measured continuously by tissue glucose sensor FreeStyle Libre 3 (Abbott) in the 4 weeks during diet A and in the 4 weeks of diet B. Counting number of hypoglycemic events during the 4 weeks of diet A and comparing to counted number of hypoglycemic events during the 4 weeks of diet B. Each tissue glucose sensor lasts 14 days, and hence the outcome measure will be assessed each 14 days, and read in the LibreView program. Assessing is performed day 15 and day 29 of diet A and day 15 and 29 of diet B.

    Time frame: Day 15 and 29 of diet A and day 15 and 29 of diet B

  6. Amino acid profile

    Levels of amino acids measured

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  7. Plasma insulin, glucose, c-peptide

    Concentration levels measured in plasma

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  8. HOMA score

    HOMA score (Homeostatic Model Assessment) including estimated beta cell function, HOMA%B (%B), insulin sensitivity, HOMA%S (%S), and insulin resistance HOMA-IR (IR), calculated from insulin, glucose and C-peptide in plasma, using an Excel spreadsheet from the University of Oxford.

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  9. HbA1c

    Concentration levels measured in blood

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  10. Cytokines in plasma

    Cytokines, chemokines and growth factors measured using Multiplex assay from BioRad Lab, Bio-Plex 27-plex kit: Interleukin (IL)-1β, IL-1RA (IL-1 receptor antagonist), IL-2, IL-4, IL-5, IL-6, IL-7, chemokine (C-X-C) motif 8 (CXCL8), IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, chemokine (C-C motif) ligand 5 (CCL5), chemokine ligand 11 (CCL11), basic fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ, CXCL10, CCL2, CCL3, CCL4, platelet-derived growth factor-BB (PDGF-BB), tumour necrosis factor (TNF) and vascular endothelial growth factor (VEGF).

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  11. Intestinal microbiota composition

    Sequencing of fecal samples, Gut Health Panel from Bio-Me, covering 100 different bacterias

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  12. Physical activity

    Accelerometer (AX3 Axivity Newcastle, UK), attached to the thigh and worn for 7 consecutive days in the first week of diet A and in the first week of diet B. Moderate to vigorous physical activity (MVPA) is detected in 5-second intervals. Measuring time (min/day) spent in MVPA during the first week of diet A and during the first week of diet B.

    Time frame: Immediately after one week of Diet A, and immediately after one week of Diet B

  13. Blood pressure

    20 min measurement

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  14. Body composition, metabolic age

    Tanita Body Composition Analyzer

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  15. Mitochondrial oxygen consumption rate

    SeaHorse, mononuclear cells in peripheral blood

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  16. ALAS1mRNA

    TaqMan gene expression assay

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  17. Urine-ALA/creatinine & urine-porphyrins

    level measurement of concentration in urine

    Time frame: Baseline before diet A and immediately after the 4 weeks of diet A, baseline before diet B and immediately after the 4 weeks of diet B

  18. Mitochondrial function-related genes

    Paxgen tubes, qPCR, Mitochondrial genome sequencing

    Time frame: At baseline immediately before each participants first diet intervention

07

Study locations

3 of 3 sites recruiting
  • Nordland Hospital Trust
    Bodø, Nordland 8092, Norway
    Recruiting
    • Elin Storjord, MD PhD · Contactelin.storjord@nordlandssykehuset.no · +4797072484
    • Hilde Thunhaug, IC nurse · Contacthilde.thunhaug@nordlandssykehuset.no · +47 95057864
    • Elin Storjord, MD PhD · Principal investigator
    • Amy Dickey, MD · Sub investigator
    • Bjørn Steen Skålhegg, PhD, Prof. · Sub investigator
    • Bård O. Karlsen, PhD · Sub investigator
    • Elin Røst, Master · Sub investigator
    • Erik Knutsen, PhD · Sub investigator
    • Hilde Thunhaug, Bachelor · Sub investigator
    • Jonas Aakre Wik, PhD · Sub investigator
    • Andersen Karl, MD, Prof. · Sub investigator
    • Pettersen Kristin, Bachelor · Sub investigator
    • Marlene B. Karlsen, Master · Sub investigator
    • Nina Lorentsen, Master · Sub investigator
    • Ole-Lars Brekke, MD,PhD,Prof · Sub investigator
    • Randolf Hardersen, MD, PhD · Sub investigator
    • Rita Laastad, Bachelor · Sub investigator
    • Steinar Daae Johansen, PhD, Dean · Sub investigator
    • Tor Erik Jørgensen, PhD · Sub investigator
    • Vegar Rangul, PhD · Sub investigator
    • Åse Emblem, PhD · Sub investigator
    • Fredrik Ellefsrud, MD · Sub investigator
    • Tor Claudi, MD · Sub investigator
    • Ingrid Joakimsen, Master · Sub investigator
    • Trine Hauglid Aardalsbakke, Master · Sub investigator
    • Guillaume Lemetais, PhD · Sub investigator
  • Studieenheten, Akademiskt Specialistcentrum, Stockholm läns sjukvårdsområde, Region Stockholm
    Stockholm, Sweden
    Recruiting
  • Norrland University Hospital
    Umeå, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Selected Individual participant data that underlie the results reported in published articles, can be accessed upon reasonable request to the principal investigator, but in each case the data will be deidentified, and the data can only be shared if it is considered that it will not be possible to reidentify persons from the data, and if in each case the data protection officer has advised it and the principal investigator has granted it. Due to Norwegian law on sensitive data, raw data of this type cannot be submitted to public repositories, e.g DNA sequencing data. Study protocol and the template for informed consent form is available upon reasonable request.

Supporting information: Study protocol, Informed consent form

Time frame: Immediately following each publication. Until 31 of December 2037

Access criteria: Reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Oct 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2024
First posted
Feb 22, 2024
StartActual
Jan 27, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2037
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06273644
Lead sponsor
Nordlandssykehuset HF
Collaborators
University of Oslo, Nord University, UiT The Arctic University of Norway, Norwegian University of Science and Technology, The University of Texas Medical Branch, Galveston, Karolinska University Hospital, University Hospital, Umeå
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Jan 27, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2037 (estimated)
Last update
Mar 27, 2026

Study contacts

Elin Storjord, MD PhD
Contact
elin.storjord@nordlandssykehuset.no
97072484
Hilde Thunhaug, Nurse
Contact
hilde.thunhaug@nordlandssykehuset.no
95057864
Elin Storjord, MD PhD
principal investigator · Nordlandssykehuset HF
Per Dahlqvist, MD PhD
principal investigator · Norrland University Hospital, Umeå
Eliane Sardh, MD PhD
principal investigator · Studieenheten, Akademiskt Specialistcentrum, Stockholm Läns Sjukvårdsområde, Region Stockholm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion